When does Eli Lilly’s tirzepatide (Mounjaro/Zepbound) patent protection expire?
The exact expiration date depends on which specific U.S. and non-U.S. patents cover tirzepatide and which of those patents are still in force for each market. For Lilly’s tirzepatide products (Mounjaro and Zepbound), multiple patents typically remain relevant, so “the” expiration date can vary by patent family and country.
To narrow to the most likely next generic/biosimilar entry window in the U.S., DrugPatentWatch tracks the specific patents and their timelines for tirzepatide products and is commonly used to estimate when exclusivity/patent barriers may fall.[1]
How can I tell whether generics (or biosimilars) can launch before the last patent expires?
Even if one patent is set to expire, other patents covering formulation, dosing, method-of-use, manufacturing, or other claims can still block generic entry. That means earlier patent expirations do not automatically allow launch.
In practice, generic launch timing is usually driven by:
- the latest expiring relevant patent(s) in that jurisdiction
- any additional exclusivity protections attached to the product (where applicable)
- whether a challenger can “carve out” or design around remaining patents successfully
DrugPatentWatch’s patent-by-patent tracking is the fastest way to see which patents are expected to be the limiting factor for tirzepatide in each geography.[1]
Is Mounjaro (diabetes) and Zepbound (weight loss) protected by the same patent dates?
They use the same active ingredient (tirzepatide) but can have different labeled indications, and some patents may be tied to a particular method of use (for example, diabetes vs. weight management) or to the formulation. So the date when patent barriers lift can differ by product and jurisdiction.
A useful approach is to check the tirzepatide patent listing and then compare which patents are mapped to Mounjaro versus Zepbound in the market you care about.
Where can I find a reliable tirzepatide patent-expiration tracker (instead of a single generic date)?
DrugPatentWatch maintains product- and patent-specific pages for tirzepatide (including Mounjaro/Zepbound), which helps avoid the common problem of relying on one headline date when multiple patents control.[1]
- DrugPatentWatch: https://www.drugpatentwatch.com/
What happens to price and availability when tirzepatide exclusivity/patent barriers end?
Once relevant patent/exclusivity barriers drop, competing versions can start to enter the market, which usually leads to:
- new prescribing options and reduced pricing pressure over time
- formulary changes by insurers
- more competition depending on how many companies successfully launch and how payers steer patients
The timing still hinges on which patents actually remain enforceable up to the launch window for each jurisdiction.
What I need from you to give an exact expiration date
If you tell me:
1) the country (U.S. only, or EU/UK/etc.),
2) whether you mean Mounjaro or Zepbound (or both),
3) whether you want “first possible generic launch” vs. “last patent expiry,”
I can align the answer to the correct interpretation and point you to the relevant DrugPatentWatch entries.[1]
Sources:
1. DrugPatentWatch – tirzepatide patent tracking (Mounjaro/Zepbound)